Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response

Vaccine

Volumn 26, Issue 3, 2008, Pages 333-344

  Ramos, I ^a   Alonso, A ^a   Marcen, J M ^b   Peris, A ^b   Castillo, J A ^b   Colmenares, M ^a   Larraga, V ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b UNIVERSIDAD DE ZARAGOZA   (Spain)

Author keywords

Canine visceral leishmaniasis; DNA vaccine; Immune response; LACK; Leishmania infantum; Modified vaccinia virus Ankara

Indexed keywords

DNA VACCINE; LACK ANTIGEN; MODIFIED VIRUS ANKARA; RECOMBINANT VACCINIA VIRUS; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CLINICAL FEATURE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; IMMUNE RESPONSE; LEISHMANIA INFANTUM; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; VACCINIA VIRUS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; DOG DISEASES; DOGS; GENETIC VECTORS; IMMUNIZATION; IMMUNIZATION, SECONDARY; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; TH1 CELLS; VACCINES, DNA; VACCINIA VIRUS;

EID: 37549005549     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.021     Document Type: Article

References (73)

1. Rioux D., Lanotte G., Serres E., Prarlong F., Bastien P., and Prieres J. Taxonomy in Leishmania: use of zymodemes. Suggestions for a new classification. Ann Parasitol Hum Comp 65 (1990) 111-125
2. Peters W., and Killick-kendrick R. The Leishmaniases in biology and medicine vol. 1 (1987), Academic Press, London p. 473-97
3. Alvar J., Canavate C., Molina R., Moreno J., and Nieto J. Canine leishmaniasis. Adv Parasitol 57 (2004) 1-88
4. Bettini S., Gramiccia M., Gradoni L., and Atzeni M.C. Leishmaniasis in Sardinia. II. Natural infection of Phlebotomus perniciosus Newstead, 1911, by Leishmania infantum Nicolle, 1908, in the province of Cagliari. Trans Roy Soc Trop Med Hyg 80 3 (1986) 458-459
5. Cabral M., O'Grady J.E., Gomes S., Sousa J.C., Thompson H., and Alexander J. The immunology of canine leishmaniosis: strong evidence for a developing disease spectrum from asymptomatic dogs. Vet Parasitol 76 3 (1998) 173-180
6. Berrahal F., Mary C., Roze M., Berenger A., Escoffier K., Lamouroux D., et al. Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting. Am J Trop Med Hyg 55 3 (1996) 273-277
7. Solano-Gallego L., Morell P., Arboix M., Alberola J., and Ferrer L. Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. J Clin Microbiol 39 2 (2001) 560-563
8. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies?. Am J Trop Med Hyg 52 3 (1995) 287-292
9. Mishra J., Saxena A., and Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 14 10 (2007) 1153-1169
10. Pasquau F., Ena J., Sanchez R., Cuadrado J.M., Amador C., Flores J., et al. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur J Clin Microbiol Infect Dis 24 6 (2005) 411-418
11. Cruz I., Nieto J., Moreno J., Canavate C., Desjeux P., and Alvar J. Leishmania/HIV co-infections in the second decade. Indian J Med Res 123 3 (2006) 357-388
12. Lasri S., Sahibi H., Sadak A., Jaffe C.L., and Rhalem A. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet Res 30 5 (1999) 441-449
13. Mayrink W., Genaro O., Silva J.C., da Costa R.T., Tafuri W.L., Toledo V.P., et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Memorias do Instituto Oswaldo Cruz 91 6 (1996) 695-697
14. Nogueira F.S., Moreira M.A., Borja-Cabrera G.P., Santos F.N., Menz I., Parra L.E., et al. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 40 (2005) 4805-4810
15. Molano I., Alonso M.G., Miron C., Redondo E., Requena J.M., Soto M., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92 1-2 (2003) 1-13
16. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 22 (2005) 2825-2840
17. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., Gramiccia M., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23 45 (2005) 5245-5251
18. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23 28 (2005) 3716-3725
19. Poot J., Spreeuwenberg K., Sanderson S.J., Schijns V.E., Mottram J.C., Coombs G.H., et al. Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum. Vaccine 24 14 (2006) 2460-2468
20. Carrillo E., Ahmed S., Goldsmith-Pestana K., Nieto J., Osorio Y., Travi B., et al. Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. Vaccine 25 8 (2007) 1534-1543
21. Moreno J., Nieto J., Masina S., Carrillo E., Canavate C., and Cruz I. Immunization with H1 and HASPB1 leishmania proteins protect dogs against experimental canine leishmaniasis. Third World Congress on Leishmaniasis Palermo. Italy (2005) 178
22. Moreno J, Nieto J, Masina S, Canavate C, Cruz I, Chicharro C, et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 2007 Jun 4.
23. Saldarriaga O.A., Travi B.L., Park W., Perez L.E., and Melby P.C. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 24 11 (2006) 1928-1940
24. Liew F.Y., Millott S., Li Y., Lelchuk R., Chan W.L., and Ziltener H. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis. Eur J Immunol 19 7 (1989) 1227-1232
25. Louis J.A., Zubler R.H., Coutinho S.G., Lima G., Behin R., Mauel J., et al. The in vitro generation and functional analysis of murine T cell populations and clones specific for a protozoan parasite, Leishmania tropica. Immunol Rev 61 (1982) 215-243
26. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 147 9 (1991) 3149-3155
27. Heinzel F.P., Sadick M.D., Mutha S.S., and Locksley R.M. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 88 16 (1991) 7011-7015
28. Holaday B.J., Sadick M.D., Wang Z.E., Reiner S.L., Heinzel F.P., Parslow T.G., et al. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. J Immunol 147 5 (1991) 1653-1658
29. Scharton T.M., and Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 178 2 (1993) 567-577
30. Ahmed S., Colmenares M., Soong L., Goldsmith-Pestana K., Munstermann L., Molina R., et al. Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immunity 71 1 (2003) 401-410
31. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., et al. Expression cloning of a protective Leishmania antigen. Science (New York, NY) 268 5210 (1995) 563-566
32. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., and Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science (New York, NY) 263 5144 (1994) 235-237
33. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186 7 (1997) 1137-1147
34. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernadina W., del Real G., and Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immunity 62 1 (1994) 229-235
35. Cabral M., O'Grady J., and Alexander J. Demonstration of Leishmania specific cell mediated and humoral immunity in asymptomatic dogs. Parasite Immunol 14 5 (1992) 531-539
36. Cabral M., McNerney R., Gomes S., O'Grady J., Frame I., Sousa J.C., et al. Demonstration of natural Leishmania infection in asymptomatic dogs in the absence of specific humoral immunity. Archives de l'Institut Pasteur de Tunis 70 3-4 (1993) 473-479
37. Barbieri C.L. Immunology of canine leishmaniasis. Parasite Immunol 28 7 (2006) 329-337
38. Vouldoukis I., Drapier J.C., Nussler A.K., Tselentis Y., Da Silva O.A., Gentilini M., et al. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the l-arginine nitric oxide pathway. Antimicrob Agents Chemother 40 1 (1996) 253-256
39. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
40. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Current Drug Targets 3 3 (2003) 263-271
41. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79 Pt 2 (1998) 347-352
42. Perez-Jimenez E., Kochan G., Gherardi M.M., and Esteban M. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect/Institut Pasteur 8 3 (2006) 810-822
43. Gonzalo R.M., Rodriguez J.R., Rodriguez D., Gonzalez-Aseguinolaza G., Larraga V., and Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect/Institut Pasteur 3 9 (2001) 701-711
44. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribanez M.A., and Castillo J.A. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol 88 1-2 (2002) 13-20
45. Cruz I., Chicharro C., Nieto J., Bailo B., Canavate C., Figueras M.C., et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol 44 7 (2006) 2343-2347
46. Maniatis T.F.E., and Sambrook J. Molecular cloning. A laboratory manual (1982), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
47. Francino O., Altet L., Sanchez-Robert E., Rodriguez A., Solano-Gallego L., Alberola J., et al. Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. Vet Parasitol 137 3-4 (2006) 214-221
48. Deplazes P., Smith N.C., Arnold P., Lutz H., and Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol 17 9 (1995) 451-458
49. Solano-Gallego L., Llull J., Ramos G., Riera C., Arboix M., Alberola J., et al. The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet Parasitol 90 1-2 (2000) 37-45
50. Santos-Gomes G.M., Rosa R., Leandro C., Cortes S., Romao P., and Silveira H. Cytokine expression during the outcome of canine experimental infection by Leishmania infantum. Vet Immunol Immunopathol 88 1-2 (2002) 21-30
51. Abranches P., Santos-Gomes G., Rachamim N., Campino L., Schnur L.F., and Jaffe C.L. An experimental model for canine visceral leishmaniasis. Parasite Immunol 13 5 (1991) 537-550
52. Campino L., Santos-Gomes G., Rica Capela M.J., Cortes S., and Abranches P. Infectivity of promastigotes and amastigotes of Leishmania infantum in a canine model for leishmaniosis. Vet Parasitol 92 4 (2000) 269-275
53. Martinez-Moreno A., Moreno T., Martinez-Moreno F.J., Acosta I., and Hernandez S. Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis. Vet Immunol Immunopathol 48 3-4 (1995) 209-220
54. Moreno J., and Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol 18 9 (2002) 399-405
55. Nieto C.G., Garcia-Alonso M., Requena J.M., Miron C., Soto M., Alonso C., et al. Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet Immunol Immunopathol 67 2 (1999) 117-130
56. Paranhos-Silva M., Oliveira G.G., Reis E.A., de Menezes R.M., Fernandes O., Sherlock I., et al. A follow-up of Beagle dogs intradermally infected with Leishmania chagasi in the presence or absence of sand fly saliva. Vet Parasitol 114 2 (2003) 97-111
57. Riera C., Valladares J.E., Gallego M., Aisa M.J., Castillejo S., Fisa R., et al. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 84 1-2 (1999) 33-47
58. Reis A.B., Martins-Filho O.A., Teixeira-Carvalho A., Carvalho M.G., Mayrink W., Franca-Silva J.C., et al. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res Vet Sci 81 1 (2006) 68-75
59. Barrouin-Melo S.M., Larangeira D.F., Trigo J., Aguiar P.H., dos-Santos W.L., and Pontes-de-Carvalho L. Comparison between splenic and lymph node aspirations as sampling methods for the parasitological detection of Leishmania chagasi infection in dogs. Memorias do Instituto Oswaldo Cruz 99 2 (2004) 195-197
60. Sanchez M.A., Diaz N.L., Zerpa O., Negron E., Convit J., and Tapia F.J. Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with Leishmania chagasi. Am J Trop Med Hyg 70 6 (2004) 618-624
61. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A., et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine 25 33 (2007) 6176-6190
62. Moreno J., Nieto J., Masina S., Canavate C., Cruz I., Chicharro C., et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25 29 (2007) 5290-5300
63. Day MJ. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet Parasitol 2007.
64. Quinnell R.J., Courtenay O., Garcez L.M., Kaye P.M., Shaw M.A., Dye C., et al. IgG subclass responses in a longitudinal study of canine visceral leishmaniasis. Vet Immunol Immunopathol 91 3-4 (2003) 161-168
65. Iniesta L., Gallego M., and Portus M. Immunoglobulin G and E responses in various stages of canine leishmaniosis. Vet Immunol Immunopathol 103 1-2 (2005) 77-81
66. Bourdoiseau G., Bonnefont C., Hoareau E., Boehringer C., Stolle T., and Chabanne L. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet Immunol Immunopathol 59 1-2 (1997) 21-30
67. Leandro C., Santos-Gomes G.M., Campino L., Romao P., Cortes S., Rolao N., et al. Cell mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis. Vet Immunol Immunopathol 79 3-4 (2001) 273-284
68. Reis A.B., Teixeira-Carvalho A., Vale A.M., Marques M.J., Giunchetti R.C., Mayrink W., et al. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol 112 3-4 (2006) 102-116
69. Cardoso L., Schallig H.D., Cordeiro-da-Silva A., Cabral M., Alunda J.M., and Rodrigues M. Anti-Leishmania humoral and cellular immune responses in naturally infected symptomatic and asymptomatic dogs. Vet Immunol Immunopathol 117 1-2 (2007) 35-41
70. Miranda S., Martorell S., Costa M., Ferrer L., and Ramis A. Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol. Vet Parasitol 144 3-4 (2007) 251-260
71. Rosypal A.C., Gogal Jr. R.M., Zajac A.M., Troy G.C., and Lindsay D.S. Flow cytometric analysis of cellular immune responses in dogs experimentally infected with a North American isolate of Leishmania infantum. Vet Parasitol 131 1-2 (2005) 45-51
72. Pinelli E., Gonzalo R.M., Boog C.J., Rutten V.P., Gebhard D., del Real G., et al. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur J Immunol 25 6 (1995) 1594-1600
73. Pinelli E., van der Kaaij S.Y., Slappendel R., Fragio C., Ruitenberg E.J., Bernadina W., et al. Detection of canine cytokine gene expression by reverse transcription-polymerase chain reaction. Vet Immunol Immunopathol 69 2-4 (1999) 121-126